A
AM Prieur
Researcher at Necker-Enfants Malades Hospital
Publications - 30
Citations - 2840
AM Prieur is an academic researcher from Necker-Enfants Malades Hospital. The author has contributed to research in topics: Juvenile rheumatoid arthritis & Neonatal onset multisystem inflammatory disease. The author has an hindex of 20, co-authored 30 publications receiving 2703 citations. Previous affiliations of AM Prieur include University of Paris.
Papers
More filters
Journal ArticleDOI
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
Nicolino Ruperto,Daniel J. Lovell,Ruben Cuttica,Nick Wilkinson,Patricia Woo,Graciela Espada,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Maria Teresa Apaz,Eileen Baildam,Anders Fasth,Valeria Gerloni,Pekka Lahdenne,AM Prieur,Angelo Ravelli,Rotraud K. Saurenmann,M.L. Gamir,Nico M Wulffraat,László Maródi,Ross E. Petty,Rik Joos,Francesco Zulian,Deborah McCurdy,Barry L. Myones,K. Nagy,Peter Reuman,Ilona S. Szer,Suzanne Travers,A. Beutler,Greg Keenan,Jason Clark,Sudha Visvanathan,Adedigbo A. Fasanmade,Aparna Raychaudhuri,Alan M. Mendelsohn,Alberto Martini,Edward H. Giannini +38 more
TL;DR: Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile for infliximab in the treatment of juvenile rheumatoid arthritis, and achievement of the primary efficacy end point at 3 months did not differ significantly between inflIXimab-treated and placebo-treated patients.
Journal ArticleDOI
Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients
Jean-Louis Stephan,Isabelle Koné-Paut,Claire Galambrun,Richard Mouy,Brigitte Bader-Meunier,AM Prieur +5 more
TL;DR: RHS may be a more common complication of systemic disease in childhood than previously thought and calls for the immediate withdrawal of potentially triggering medications, anti-infective therapy when relevant, and urgent immunosuppressive treatment, measures that are very often effective.
Journal ArticleDOI
Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
P Woo,Taunton R. Southwood,AM Prieur,Caroline J Doré,J. Grainger,J. David,C. Ryder,Nathan Hasson,A. Hall,I. Lemelle +9 more
TL;DR: MTX 15-20 mg/m2 given orally once a week was found to be an effective treatment for both extended oligoarticular and systemic JIA in this shortterm trial and long-term efficacy needs to be addressed in future studies.
Journal ArticleDOI
A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients.
AM Prieur,C Griscelli,F Lampert,H Truckenbrodt,M A Guggenheim,Daniel J. Lovell,P Pelkonnen,J Chevrant-Breton,B M Ansell +8 more
TL;DR: A high frequency of prematurity with features resembling a foetal infection was observed but no proof of a possible causal virus has so far been found so that etiology remains unknown.
Journal ArticleDOI
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Bénédicte Neven,Isabelle Marvillet,Céline Terrada,Alice Ferster,Nathalie Boddaert,Vincent Couloignier,Graziella Pinto,Anne Pagnier,Christine Bodemer,Bahram Bodaghi,Marc Tardieu,AM Prieur,Pierre Quartier +12 more
TL;DR: The present results indicate that anakinra treatment is effective over the long term in NOMID/CINCA syndrome, however, treatment has to be initiated before irreversible lesions develop, and, particularly in very young patients, dosage adjustment is required.